Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharma) reported that its share capital structure remained unchanged in March 2026.

The company’s authorised share capital stood at HKD 1.00 billion, representing 100.00 billion ordinary shares with a par value of HKD 0.01 each—identical to the previous month.

Issued share capital was steady at 9.15 billion ordinary shares, while treasury shares were unchanged at 184.01 million. Consequently, the total number of shares in issue, including treasury shares, remained 9.33 billion.

No new shares were issued, repurchased, or cancelled during the month. Likewise, no treasury shares were transferred or sold. Total funds raised from option exercises were HKD 0.

Outstanding share options under the 24 October 2017 schemes were unchanged: 60.59 million options exercisable at HKD 0.972 and 7.50 million options at HKD 2.22. The aggregate pool of shares that may be issued upon future option grants under the schemes remained at 844.95 million.

Management confirmed compliance with the Main Board’s minimum 25 % public-float requirement as of 31 March 2026.

The filing was submitted by Executive Director and Joint Company Secretary Ms. Chen Yanling on 1 April 2026.